Silent bacterial genes yield potential leads for future cancer drugs

Researchers at the Helmholtz Center for Infection Research (HZI) and the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) have uncovered a new family of natural compounds with potential anticancer properties. By activating silent gene clusters in bacteria, the team identified these molecules and mapped their unusual biosynthetic pathway. The findings, published in a leading journal, could open new avenues for drug development. The researchers also developed a synthetic method to produce the compounds, overcoming limitations of natural extraction. This work highlights the untapped potential of microbial genomes for discovering novel therapeutics. As antibiotic resistance rises and cancer remains a leading cause of death, such discoveries are crucial. The next step involves testing these compounds in preclinical models to assess efficacy and safety. If successful, they could lead to new cancer treatments in the coming years.